- Future Pak, a privately held contract manufacturer and packager of pharmaceutical and nutraceutical products, has disclosed its intention to acquire Theratechnologies (TSX:TH), a biopharma company focused on oncology and HIV
- The most recent offer up to C$255 million entails a premium of 164 to 238 per cent to Theratechnologies’ stock price of C$1.33 as of April 10, 2025
- Theratechnologies stock has added 31.03 per cent year-over-year but remains down by 72.41 per cent since 2020
Future Pak, a privately held contract manufacturer and packager of pharmaceutical and nutraceutical products, has disclosed its intention to acquire Theratechnologies (TSX:TH), a biopharma company focused on oncology and HIV.
There have been two proposals to date, each at an over 100 per cent premium, neither of which have received formal responses. The most recent up to C$255 million offer includes a cash consideration of C$3.51 to C$4.50 per share, contingent on gross profits, entailing a premium of 164 to 238 per cent to Theratechnologies’ stock price of C$1.33 as of April 10, 2025.
According to Friday’s news release, “by publicly disclosing its interest, Future Pak hopes to encourage Theratechnologies shareholders to engage with the proposal and ensure that the board fulfills its duty to pursue the highest value outcome available.”
“To move this process forward efficiently and deliver compelling value to Theratechnologies’ shareholders, we have submitted multiple offers outlining a flexible and attractive framework,” Nirav Patel, chief growth officer at Future Pak, said in a statement. “We believe this proposal provides significant upside and a solid foundation for constructive dialogue, with the goal of achieving a mutually beneficial transaction.”
Theratechnologies’ income statements reveal an increasingly efficient business marked by a significant reduction in operating losses and pivot to net income profitability over the past three years. The company’s flagship Egrifta – to reduce abdominal fat in HIV patients with lipodystrophy – has done most of the leg work here, followed by its Trogarzo product serving multidrug-resistant HIV patients, as evidenced in Q1 2025 financial results.
Readers can turn to the company’s January 2025 investor presentation to continue their due diligence and gain insights about its oncology and HIV drug development pipeline.
Theratechnologies stock (TSX:TH) is up by 43.78 per cent on the news trading at C$2.66 per share as of 11:27 am ET. The stock has added 31.03 per cent year-over-year but remains down by 72.41 per cent since 2020.
Join the discussion: Find out what everybody’s saying about this biopharma stock on the Theratechnologies Inc. Bullboard and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image, generated by AI: Adobe Stock)
